Karim Fizazi
Institut Gustave Roussy
770 Papers
3.2K Citations
Karim Fizazi is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Prostate cancer & Medicine. The author has an hindex of 96, co-authored 658 publications. Previous affiliations of Karim Fizazi include Université Paris-Saclay & University College London.
Chat about Author
Papers
Efficacy and safety of abiraterone acetate plus prednisone and androgen deprivation therapy +/- docetaxel in older patients (≥70 years), with de novo metastatic-castration sensitive prostate cancer, compared to younger patients (<70 years): The PEACE-1 trial.
Loic Mourey,Helen Boyle,Guilhem Roubaud,Ray McDermott,Stéphane Supiot,Bertrand Tombal,Aude Flechon,Dominik Berthold,Philippe Ronchin,Gabriel Kacso,J. F. Berdah,Fabio Calabrò,Gwenaelle Gravis,Samuel Palumbo,Thierry Gil,B. Vie,H Ribault,Karim Fizazi,Stéphanie Foulon,Joan Carles +19 more
TL;DR: In this article , the safety and efficacy of abiraterone acetate + prednisone (AAP) in older (≥ 70 years) and younger (< 70 years), patients in PEACE-1 was investigated.
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015
Silke Gillessen,Aurelius Omlin,Gerhardt Attard,J.S. de Bono,Eleni Efstathiou,Eleni Efstathiou,Eleni Efstathiou,Karim Fizazi,Susan Halabi,Peter S. Nelson,Oliver Sartor,Matthew R. Smith,Howard R. Soule,Hideyuki Akaza,Tomasz M. Beer,Himisha Beltran,Arul M. Chinnaiyan,Gedske Daugaard,Ian D. Davis,M. De Santis,Charles G. Drake,Rosalind A. Eeles,Stefano Fanti,Martin E. Gleave,Axel Heidenreich,Maha Hussain,Nicholas D. James,Nicholas D. James,Frédéric Lecouvet,Christopher J. Logothetis,Ken Mastris,Sten Nilsson,William Oh,David Olmos,Anwar R. Padhani,Chris Parker,Mark A. Rubin,Jack A. Schalken,Howard I. Scher,Howard I. Scher,Avishay Sella,N. Shore,Eric J. Small,Cora N. Sternberg,Hiroyoshi Suzuki,Christopher Sweeney,Ian F. Tannock,Bertrand Tombal +47 more
TL;DR: The first St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) Expert Panel identified and reviewed available evidence for the ten most important areas of controversy in advanced prostate cancer management.
STEAP, a prostate tumor antigen, is a target of human CD8+ T cells
Pedro M. S. Alves,Olivier Faure,Stéphanie Graff-Dubois,Sébastien Cornet,Irena Bolonakis,David-Alexandre Gross,Isabelle Miconnet,Salem Chouaib,Karim Fizazi,Jean-Charles Soria,François A. Lemonnier,Kostas Kosmatopoulos +11 more
TL;DR: Results show that STEAP can be a target of anti-tumor CD8+ T cells and thatSTEAP peptides can be used for a broad-spectrum-Tumor immunotherapy.
Results from a phase 3, randomized, double-blind, multicenter, placebo-controlled trial of orteronel (TAK-700) plus prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC) that has progressed during or following docetaxel-based therapy (ELM-PC 5 trial).
Robert Dreicer,Robert Jones,Stéphane Oudard,Eleni Efstathiou,Fred Saad,Ronald de Wit,Johann S. de Bono,Yuanjun Shi,Bindu Tejura,David B. Agus,Niels Geert Borgstein,Joaquim Bellmunt,Karim Fizazi +12 more
TL;DR: The study was terminated for failing to meet its primary endpoint: median overall survival (OS) was 17.0 months and safety (NCT01193257).